|Bid||0.00 x 800|
|Ask||0.00 x 1400|
|Day's Range||53.49 - 54.39|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||96.15|
|Forward Dividend & Yield||1.60 (2.92%)|
|1y Target Est||N/A|
This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...
Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
Bristol-Myers (BMY) announces positive results on oncology drug Empliciti. The company's blockbuster drug, Opdivo, was also approved in China for lung cancer.
Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.
Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.
Bristol-Myers Squibb Company (NYSE:BMY) is currently trading at a trailing P/E of 94.7x, which is higher than the industry average of 23.7x. Although some investors may jump to the conclusionRead More...
The Hutch leased more than 100,000 square feet of space in the facility, bringing the cancer research center's South Lake Union footprint to 1.44 million square feet.
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
When it was last covered in mid-May, few biotech investors questioned the valuation and prospects for Nektar Therapeutics (NASDAQ:NKTR) as shares held the $80 level. Such a quick drop is typical for any stock that rose by more than four-fold in under a year, but in the case of Nektar, investors are misinterpreting the clinical results. Nektar Therapeutics’ nearly 42 percent drop on June 4 now implies a more than two-fold upside for investors.
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
The latest results from a collaboration testing Bristol-Myers Squibb’s cancer drug Opdivo with Nektar Therapeutics’ NKTR-214 didn’t exactly impress investors. Wall Street analysts described the phase 1/2 clinical trial data as “underwhelming” and “immature,” and Nektar (NKTR) shares plummeted 41.8 on Monday. Combination treatments that pair two cancer drugs in an effort to boost their effect are an important trend in cancer research right now.
Shares plummeted after investors and Wall Street analysts found Nektar's mid-stage trial results for its collaborative effort with Bristol-Myers Squibb Co. to combine Nektar's NKTR-214 top immune-oncology program with Bristol-Myers' Opdivo drug to be below expectations. Response rates for patients with melanoma and kidney cancer patients decreased, according to the study that was released to the American Society of Clinical Oncology (ASCO) over the weekend.
Nektar's market cap, which was over $15 billion by Friday's close, fell to $9 billion by Monday's close. The fall came after data released Saturday suggested patients diagnosed with melanoma aren't reacting to the company's experimental treatment as well as earlier samples did. Shares of biotech company Nektar Therapeutics NKTR lost nearly half their value Monday after the company gave a clinical trial update that fell well short of investor expectations.
Technology stocks led the market higher on Monday as Apple and Microsoft boosted the sector after the iPhone maker kicked off its annual developers conference and the Windows software maker announced an acquisition. Apple unveiled its latest operating system iOS 12 at the conference and even after paring some gains in the afternoon, for a 0.8 percent gain, it still provided the biggest boost to the S&P 500 and helped take the Nasdaq close to its intraday record reached in mid-March.
Bristol-Myers Squibb Company (NYSE:BMY) shares were declining Monday as the company joined forces with another company to develop a cancer drug that’s been disappointing so far. The result was underwhelming as Wall Street investors were not impressed by the end result. Analysts said that the phase 1/2 clinical trial data was “underwhelming” and “immature,” sending both stocks dropping early Monday.
Nektar Therapeutics shares plummeted 39% Monday morning after the San Francisco-based biotech company released disappointing clinical trial results over the weekend regarding its key product, NKTR-214. Tests showed that response rates in cancer patients treated with a combination of NKTR-214 and the Bristol-Myers Squibb (BMY) drug Opdivo declined from previous studies. “214 may not be adding an incremental benefit,” wrote Joshua Schimmer of Evercore ISI Research in a note today.
This study seeks to determine the effectiveness of combining Bristol-Myers Squibb Co (NYSE:BMY) Opdivo with Nektar Therapeutics NKTR-214. The clinical trail is specifically looking at treating patients with melanoma, renal cell, urothelial, non-small cell lung and triple negative breast cancers. The results included changes for three tumor types.